Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities

Zeinab Mohseni Afshar | Arefeh Babazadeh | Alireza Janbakhsh | Feizollah Mansouri | Terence T. Sio | Mark J. M. Sullman | Kristin Carson-Chahhoud | Rezvan Hosseinzadeh | Mohammad Barary | Soheil Ebrahimpour

1Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
4Department of Social Sciences, University of Nicosia, Nicosia, Cyprus
5Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus
6Australian Centre for Precision Health, University of South Australia, Adelaide, Australia
7Student Research Committee, Babol University of Medical Sciences, Babol, Iran

Correspondence
Soheil Ebrahimpour, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Ganjafrooz Blvd., Babol 4717647745, Iran.
Email: drsoheil1503@yahoo.com

Summary
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

Rev Med Virol. 2022;32:e2309. wileyonlinelibrary.com/journal/rmv © 2021 John Wiley & Sons Ltd.
1 | INTRODUCTION

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in many individuals becoming infected, more than four million deaths, and has placed an unprecedented burden on public health services worldwide.\(^1,3\) Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials.\(^5\) Table 1 summarises the current Covid-19 vaccination recommendations in these special populations and patients with existing comorbidities. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations using available research evidence.

2 | RHEUMATOLOGIC AND AUTOIMMUNE DISORDERS

Individuals on immunosuppressive therapies are among those most susceptible to Covid-19-related morbidity and mortality. Although vaccinating these populations should be a high priority for healthcare providers and governments, they have mostly been excluded from vaccine trials.\(^5\) The most important reason behind such exclusions is that immunosuppressive therapies can impair the vaccine-induced humoral and cellular immune responses, making it difficult to measure its effectiveness on the immune system.\(^6\) It is important to note that there are many such diseases, and we do not fully understand the pathogenesis of any of them. Thus, it is essential to consider the diseases and the treatments for them when considering vaccination. For example, does the disease or treatment suppress T cell or B cell responses, and will this differ according to the vaccine used? In the following section, we discuss the impact of several immunosuppressive agents on vaccine response. It is essential to know that some of the information has been generalised from experiences with influenza, pneumococcal, and tetanus vaccines.

The effect of corticosteroids on vaccine-induced antibody production is dose-dependent. Prednisolone doses higher than 10 mg daily, or equivalent doses of other corticosteroids, impair vaccine response, and thus, tapering the dose around the time of vaccination would appear necessary.\(^7\) Disease-modifying antirheumatic drugs (DMARDs) are agents used for decreasing inflammation in rheumatic disorders. Methotrexate (MTX), hydroxychloroquine, sulfasalazine, leflunomide, cyclophosphamide, mycophenolate, and azathioprine are examples of these agents.\(^8\) All DMARDs can affect antibody responses, but none of them, except MTX and cyclophosphamide, lower immunologic responses below the threshold of seroprotection.\(^8\) In addition, MTX suppresses humoral response by interacting with the B cell activation factor (BAFF).\(^9\) Thus, it is reasonable to withhold MTX for at least two weeks before and after vaccination. However, withholding the medication for more than two weeks may lead to a flare-up in the underlying disease.\(^10\) Thus, the timing of withholding medication should be carefully monitored to lower the risk of adverse events.

Anti-tumour necrosis factors (TNFs) and interleukin (IL)-17 blockers seem to have no significant effect on vaccine-induced immunity unless used concurrently with MTX.\(^11,12\) IL-6 inhibitors, such as tocilizumab (TCZ), seem to have no substantial effect on vaccine-induced seroprotection unless co-administered with MTX.\(^13\) However, while some studies have reported there should be at least 12 weeks between tocilizumab administration and vaccination to have the ideal antibody response,\(^13\) other research has shown that TCZ does not impair antibody production for other types of vaccines (not Covid-19).\(^14\) Information about the impact of IL-1 antagonists, including anakinra, and canakinumab, on vaccine-induced seroprotection, is scarce, and more studies are urgently needed.\(^15\) Janus kinase (JAK) inhibitors, such as baricitinib and tofacitinib, might trigger drug interactions with mRNA vaccines, primarily when used concurrently with MTX.\(^16\) Therefore, it is better to withhold JAK inhibitors for 1–2 weeks on either side of the vaccination date.\(^16\) Anti-CD20 agents (e.g., rituximab) impair B cell production, making patients prone to severe forms of Covid-19. These agents are also believed to profoundly affect vaccine-induced antibody responses, even several months after their use.\(^17\) Therefore, it is recommended that their use be limited only to essential cases or administered with a minimum gap of four weeks before and six months after vaccination.\(^17\) The impact of T-cell lymphocyte activation inhibitors, such as abatacept (ABA), on vaccine-induced immunity, is controversial and more studies are needed to clarify any interactions.\(^18\)

In general, TNF inhibitors, such as TCZ, ABA, and IL-17 antagonists, seem to impact vaccine efficacy negatively. The Centers for Disease Control and Prevention (CDC) recommends at least a two-week spacing between administration of these agents and vaccination.\(^14\) Thus, the decision to vaccinate rheumatologic patients who use the medications mentioned above should be individually made since it appears that low-dose immunosuppressive agents do not significantly affect the vaccine-induced antibody response.\(^14\) Overall, it appears best to vaccinate these patients when their underlying disease is under control.\(^14\) It is also noteworthy that allergic reactions in these patients may happen following vaccination, especially in patients with systemic lupus erythematosus (SLE), necessitating a more extended period (at least 2 h) of monitoring following vaccination.\(^14\)

Another important consideration is the safety profile of the Covid-19 vaccines in rheumatology patients, which do not seem to be contraindicated since none of the treatments attenuate vaccines.\(^19\) However, it is currently unknown whether Covid-19 vaccines can...
| Vaccine platform | mRNA | Adenoviral vector |
|------------------|------|------------------|
| **Most common side effects** | Fatigue, headache, chills, muscle pain, fever. Worsen after the second dose. | Injection site pain, fever, muscle aches, headache, fatigue. Worsen after the second dose. |
| **Who should not be vaccinated** | People with a history of allergic reactions to vaccine ingredients, including polyethylene glycol, and anyone with a history of allergic reactions to polysorbate. | Anyone with a severe allergic reaction to an ingredient in the vaccine. |
| **Significant side effects (rare)** | Pfizer/BioNTech and Moderna: Anaphylaxis, Bell’s palsy, autoimmune hepatitis, myocarditis, pericarditis | Janssen: VITT, demyelinating Oxford/AstraZeneca: VITT, transverse myelitis, demyelinating |

### Rheumatologic and autoimmune diseases
- Corticosteroids: Taper to <10 mg/day prior to vaccination.
- MTX: Withhold 2 weeks before and after vaccination.
- Anti-TNF and IL-17 medications: No specific dose reduction is required.
- Anti-IL-6 medications: Vaccination should be 12 weeks before/after TCZ administration.
- JAK inhibitors: Withhold 1–2 weeks before and after vaccination.
- Anti-CD20 medications: Withhold 4 weeks before until 6 months after vaccination.
- ABA: Data are not yet available.

### Cancer
- Anti-CD20 or cytotoxic therapies inactivate the mRNA vaccine.
- Cytotoxic chemotherapy: 2 weeks after vaccination.
- If chemotherapy has already been given, vaccination should be given between courses of chemotherapy.
- Lymphocyte or plasma cell-depleting regimens: Vaccination should be 2 weeks before or 3 months after the end of treatment.

### Transplant patients
- Vaccination is recommended early in the course of the underlying disease.
- After transplantation, postpone vaccination for 3–6 months.
- If the first dose is received before the transplantation, the second dose should be administered at least 4 weeks after transplantation.
- A third dose may be warranted for optimal immunity.

### CLD
- Recommended, with priority given to patients with higher MELD scores.
- Vaccination of patients with CLD undergoing treatment for HBV, HCV, PBC, and autoimmune hepatitis should be performed without discontinuing their therapy.
- Vaccination is safe and recommended for patients with HCC.
- Patients on the transplant list should receive two doses of the vaccine before the transplant.

(Continues)
| Vaccine platform | mRNA | Adenoviral vector |
|------------------|------|------------------|
| **ESRD** | **Taper steroid doses below 20 mg prednisone equivalent daily before vaccination.** | **Taper steroid doses below 20 mg prednisone equivalent daily before vaccination.** |
| | **If the patient received anti-CD20 medication, vaccination should be delayed for at least 6 months after the last dose of the therapy.** | **If the patient received anti-CD20 medication, vaccination should be delayed for at least 6 months after the last dose of the therapy.** |
| | **If an active underlying disease is present in these patients, immunosuppressive therapy is prioritised over vaccination.** | **If an active underlying disease is present in these patients, immunosuppressive therapy is prioritised over vaccination.** |
| **Neurologic disorders** | **Vaccination is recommended for MS patients.** | **Vaccination is recommended for MS patients.** |
| | **MS patients receiving ocrelizumab can receive the vaccine 4–6 weeks before starting the treatment or 4–6 months after ending the treatment.** | **MS patients receiving ocrelizumab can receive the vaccine 4–6 weeks before starting the treatment or 4–6 months after ending the treatment.** |
| | **DMTs for MS can reduce the antibody response of vaccines.** | **DMTs for MS can reduce the antibody response of vaccines.** |
| | **Patients receiving IRT, including alemtuzumab, rituximab, and ocrelizumab, can be vaccinated 6 months after the treatment.** | **Patients receiving IRT, including alemtuzumab, rituximab, and ocrelizumab, can be vaccinated 6 months after the treatment.** |
| | **In high-dose or long-term treatments with corticosteroids, vaccination is allowed 4–6 weeks after cessation of the treatment.** | **In high-dose or long-term treatments with corticosteroids, vaccination 4 to 6 weeks after cessation of treatment** |
| | **CDC recommended mRNA vaccines for GBS patients.** | **For GBS patients, data are not yet available.** |
| **Psychiatric disorders** | **Recommended, but no studies have been performed solely on the Covid-19 vaccines and neuropsychiatric disorders.** | **Recommended, but no studies have been performed solely on the Covid-19 vaccines and neuropsychiatric disorders.** |
| | **Antipsychotic agents suppress vaccine-induced antibody formation.** | **Antipsychotic agents suppress vaccine-induced antibody formation.** |
| | **Antidepressant therapy would normalise the vaccine-induced immune response.** | **Antidepressant therapy would normalise the vaccine-induced immune response.** |
| **DM** | **Recommended. Patients with DMT2 are prioritised higher than patients with DMT1.** | **Recommended. Patients with DMT2 are prioritised higher than patients with DMT1.** |
| **Obesity** | **Recommended** | **Recommended** |
| **CVD** | **Recommended** | **Recommended** |
| **HIV** | **Recommended** | **Data not yet available.** |
| **COPD** | **Recommended** | **Recommended** |
| **Current smokers** | **Recommended** | **Recommended** |
| **Pregnancy and breastfeeding** | **Recommended** | **Janssen: Individualised risk/benefit assessment should be performed before vaccination.**
**Oxford/AstraZeneca: Data are not yet available.** |
| **Elderly** | **Recommended** | **Recommended** |
| **Children** | **Pfizer/BioNTech: FDA recommends this vaccine for adolescents 12–18 years of age.**
**Moderna: Data are not yet available.** | **Data is not yet available.** |
trigger autoimmunity by direct immune-activating or non-specific adjuvant effects, leading to the exacerbation of rheumatologic or autoimmune disorders. Such events may follow the Pfizer/BioNTech vaccine administration. Nonetheless, as the benefits of vaccinating vulnerable individuals outweigh the risk of exacerbating rheumatic disorders, the American College of Rheumatology recommends vaccination against Covid-19 in all eligible rheumatologic patients. Some have hypothesised that protein subunit vaccines, such as the Novavax vaccine candidate, will have better efficacy and safety profiles for rheumatologic, autoimmune, and autoinflammatory patients.

3 | CANCER

Patients with cancer are particularly vulnerable to adverse outcomes from moderate and severe Covid-19 infections, which may be due to their underlying malignancy, cytotoxic chemotherapy, radiotherapy, other existing comorbidities, and advanced age. We must consider the diseases and their treatments when considering vaccination. For example, some treatments may impair cellular or humoral immunity to affect the overall vaccine response. It should also be noted that these effects might differ according to the vaccine used. Leukaemia, non-Hodgkin's lymphoma, and lung cancer are the most commonly seen malignancies related to severe Covid-19 cases. Therefore, owing to the relatively high fatality rate of Covid-19 in active cancer patients, this group is among the most highly prioritised to be vaccinated against the disease. Currently, there is no preferred Covid-19 vaccine for these patients, and so these individuals can receive any approved vaccine under their physician’s supervision.

In general, although it is believed that the natural- or vaccine-induced antibody response in cancer patients is suboptimal, especially among those with haematologic malignancies, there are no absolute contraindications to the Covid-19 vaccine in cancer patients undergoing glucocorticoid therapy, chemotherapy, radiotherapy, hormonal therapy, immunotherapy, or surgery. The efficacy of mRNA vaccines in patients with solid tumours and haematological malignancies has been reported to be 83% and 72%, respectively. Anti-CD20 or cytotoxic therapies in these patients is thought to be the reason for the lower-than-expected immune response in cancer patients, making mRNA vaccines less effective in these patients. However, the T-cell response induced by current vaccines is strong enough to recommend immunisation in these patients, except during the intensive phase of chemotherapy. Thus, carefully considering the timing and interval between the vaccine and the last cycle of chemotherapy would be an essential factor in the adequate vaccine immune response in this population. For patients planning to start cytotoxic chemotherapy, it is better to administer the first dose of the vaccine at least two weeks before initiating the first chemotherapy cycle. However, for those already on cytotoxic chemotherapy, the first dose of the vaccine can be administered between chemotherapy cycles. Furthermore, since these immunocompromised patients mount insufficient antibody response after natural SARS-CoV-2 infection and consequently shed the virus for a more extended period, vaccinating these individuals is vital in arresting the virus cycle, further validating the importance of vaccinating as many cancer patients in the community as possible.

Several potential concerns regarding using checkpoint inhibitors and targeted therapies, such as tyrosine kinase inhibitors, including erlotinib and imatinib, and its potential interference with viral vaccines exist. However, there is no reported data at this time. The prevalence of immune-related adverse events (IRAEs) following vaccination is unknown for checkpoint inhibitors, yet this side effect may occur within 2–3 days following vaccination. Therefore, avoiding vaccination may be reasonable in cases of significant concern. Patients receiving lymphocyte or plasma cell-depleting regimens should delay Covid-19 vaccination for at least 3 months following the end of their immunotherapeutic treatment to get the best antibody response. However, if they are about to start these regimens, it is reasonable to administer the first dose of the vaccine at least two weeks before starting the immunotherapy course. It is also believed that the Covid-19 vaccine is safe and effective in patients undergoing radiation therapy. At the beginning of the pandemic, there were significant concerns regarding clinical resource distribution and keeping patients safe from Covid-19 infections. However, the clinical burden has substantially reduced since vaccines became available.

Another important issue in patients receiving active systemic therapies is the occurrence of post-vaccination fever. However, any fever should not necessarily be attributed to vaccine response since
other differential diagnoses, like neutropenic fever, Covid-19 infection, post-surgical complications, and underlying cancer relapse may also be responsible. In addition, it is possible that the vaccinated individuals, including immunocompromised patients, may acquire SARS-CoV-2 with or without prior infection history. Therefore, adhering to preventive measures, such as hand hygiene, face coverings, and social distancing, are still likely to be necessary for everyone in the foreseeable future.

4 | TRANSPLANT PATIENTS

Transplant recipients are another at-risk group that should be prioritised for getting vaccinated since they have an increased risk of infection and developing more severe forms of Covid-19. However, these patients have not been included in the vaccine trials to date, and therefore vaccine safety, efficacy, and durability profiles have not been measured in these patients. Nevertheless, considering the consequences of severe Covid-19 in this population and the previous experiences with other vaccines, such as influenza vaccines, in stable transplant patients, the benefits of vaccination outweigh the possible side effects. Therefore, SARS-CoV-2 vaccination is strongly recommended for these patients. Nonetheless, it is also probable that the immunosuppressed condition in these patients may cause a lower anti-SARS-CoV-2 antibody response, depending on the period since the transplantation, the intensity of the immunosuppression, and the type of transplantation.

The conditioning and maintenance of immunosuppressive regimens and their dosing and intensity vary significantly between solid organ transplant (SOT) recipients and haematopoietic stem cell transplant (HSCT) recipients. It has been suggested that antiretroviral maintenance therapy can lead to a weaker post-vaccination antibody response than other regimens. Therefore, those patients should be vaccinated early in the course of their underlying disease, as the timing of vaccination is a significant factor in determining its effectiveness. Also, it is better to postpone vaccination to at least 3–6 months after transplantation when the immunosuppression is lower. Nevertheless, if the first dose of the vaccine is received before transplantation, the second dose should be postponed until at least four weeks post-transplant.

Some experts believe that a third dose is needed in transplant patients, considering shorter longevity and lower antibodies’ efficacy. A recent randomised placebo-controlled trial showed that a third dose of the mRNA-1273 (Moderna) vaccine could significantly increase the anti-receptor-binding domain (RBD) antibody levels and anti-SARS-CoV-2-specific T-cell counts in transplant patients, indicating a higher humoral and cellular immunity triggered after a third dose of the vaccine. There is also evidence of a difference in the antibody response from different vaccines, with the mRNA-1273 (Moderna) vaccine being found to result in a more significant immune response in transplant recipients. In general, vaccination is not contraindicated in stable transplant recipients, except live-attenuated vaccines, which might lead to disseminated infection, especially when their immunosuppression condition is highest, usually occurring in the first 3–6 months after the transplant. Fortunately, none of the current Covid-19 vaccines are live-attenuated, meaning it is possible to administer the vaccine to this vulnerable population. Apart from vaccine-related efficacy, durability, and safety issues, vaccine-associated allograft rejection is a unique concern in this population, although this has not been reported with any Covid-19 vaccines. Nevertheless, although extremely rare, there would appear to be a slight chance of stimulating immunologic rejection reactions via the vaccination-induced immune response.

5 | CHRONIC LIVER DISEASES

Patients with chronic liver disorders (CLD), including cirrhosis, hepatobiliary malignancies, and transplant candidates (or recipients), are vulnerable populations at risk of more severe forms of Covid-19 and higher mortality. This population needs special attention due to their underlying disease, and many operations or treatments were delayed due to the hospitals being overwhelmed or not wanting to put patients at more risk. Therefore, vaccination should also be a priority for these patients. Vaccination seems to be safe in stable CLDs, such as compensated cirrhosis and viral hepatitis. Moreover, individuals with decompensated cirrhosis, liver malignancies, and liver transplant patients should also be prioritised for vaccination using the Child-Turcotte-Pugh or the Model for End-stage Liver Disease (MELD) scores. The higher the scores, the sooner they should get the vaccine. However, the extent of the vaccine-induced immune response is unknown and expected to be suboptimal in these patients due to their underlying disease and the medications they use. It is also noteworthy that mRNA Covid-19 vaccines are expected to have favourable safety and efficacy profiles in these patients.

Patients with CLD who are on medical treatment for hepatitis B virus (HBV), hepatitis C virus (HCV), primary biliary cholangitis (PBC), or autoimmune hepatitis do not need to stop therapy in order to receive Covid-19 vaccines. Moreover, patients with hepatocellular carcinoma (HCC) on locoregional (i.e., imaging-guided liver tumour-directed procedures) or systemic therapy can also be vaccinated without pausing their treatment. Nevertheless, in recent infections or fever cases, vaccination should be delayed until the condition is stable. However, the use of immune checkpoint inhibitors (ICI) in patients with some liver diseases (e.g., HCC) is still a concern that should be further studied since immune-related adverse reactions are a possible result of vaccine interactions with ICI. Moreover, the timing of the vaccination in hepatobiliary cancer patients is heavily dependent on the stage of the malignancy, types of medication, and concomitant comorbidities. Patients with CLD on the waiting list for transplantation should receive two doses of the vaccine, preferably before the transplant. However, they should be encouraged to receive the vaccine even if their second is scheduled after the
liver transplant. However, for these patients, the time interval between the two doses of the vaccine does not necessarily need to be four weeks, and the second dose should be planned after transplant (e.g., within 6 weeks). Moreover, following liver transplantation, the best time to be vaccinated would be when the immunosuppression has been attenuated and other prophylactic medications are withheld, ideally six weeks to three months post-liver transplantation. In order to prevent acute cellular rejection (ACR), liver transplant recipients should not discontinue their immunosuppressive medications solely to achieve a favourable immune response after vaccination. Moreover, Covid-19 vaccinations should be withheld in liver transplant recipients with active ACR or those receiving high-dose corticosteroids until the condition is resolved.

6 | END-STAGE RENAL DISEASE

Patients with end-stage renal disease (ESRD) are also more prone to infection with Covid-19 due to their regular or occasional dialysis sessions, where they are exposed to a densely populated environment with a high possibility of SARS-CoV-2 transmission. Moreover, these patients may present with atypical manifestations of SARS-CoV-2 infection, leading to a delay in diagnosing the disease. In addition, patients often have multiple comorbidities and higher rates of polypharmacy. Therefore, the risk of developing a severe or lethal SARS-CoV-2 infection is likely higher in this population, and vaccinating them early against Covid-19 is highly recommended. Moreover, although ESRD patients develop seroconversion following vaccination, they are well-established to achieve a less robust and perhaps less durable antibody response. The seropositivity rate after SARS-CoV-2 vaccination does not appear to differ between haemodialysis and peritoneal dialysis (PD) patients. The extent of the immune response to SARS-CoV-2 vaccination depends on the vaccine type, the time spent since ESRD onset, and possibly age, body mass index (BMI), and nutritional status, as indicated by serum albumin and iron levels. With that in mind, several studies have suggested that a third or booster dose of vaccine would be necessary for these individuals to produce an optimal antibody response.

There does not appear to be a preference for one vaccine type over another, with adenoviral vector vaccines, such as the ChAdOx1 nCoV-19 (Oxford/AstraZeneca) vaccine, and the mRNA vaccines (i.e., Pfizer/BioNTech, and Moderna) used for vaccinating ESRD patients. In addition, patients with autoimmune renal diseases (e.g., IgA nephropathy) undergoing anti-CD20 therapy (e.g., rituximab) should replace their immunosuppressive treatment with another non-interfering regimen until a few weeks after vaccination. For example, it is reasonable for these individuals to taper steroid doses below 20 mg prednisone (or equivalent) daily or wait for at least six months after the last rituximab dose before being vaccinated. However, if their underlying disease is active, the immunosuppressive therapy is prioritised over-vaccination, although the activation or relapse of the underlying autoimmune kidney disease has only rarely been reported following vaccination.

7 | NEUROLOGIC DISORDERS

Like individuals with many chronic disorders, neurological patients are at increased risk of severe Covid-19 infection, complications, and mortality. Patients with Alzheimer disease, Parkinson disease, motor neuron diseases, central nervous system (CNS) disorders, neuromuscular disorders (NMDs), and autoimmune disorders, including multiple sclerosis (MS), myasthenia gravis (MG), and Guillain-Barré syndrome (GBS), are among the most concerning neurological disorders. Thus, vaccination against Covid-19 is vital for this population, but vaccination risks and adverse events must be carefully monitored. For example, there is some concern that vaccination against SARS-CoV-2 may exacerbate MS by inducing immunological responses and triggering immunological reactions. Nonetheless, vaccines are generally safe in MS patients, and following vaccination, there is a low probability of acute relapse, although there have been some reports of MS symptom aggravation (pseudo-relapse).

Patients with a history of GBS and autoimmune conditions should receive mRNA Covid-19 vaccines, if not contraindicated. However, it is generally believed that some of the disease-modifying therapies (DMTs) used to treat MS could reduce the antibody response following vaccination. Moreover, these medications can affect the safety and efficacy of the vaccines. Patients being treated with β-interferons, glatiramer acetate, teriflunomide dimethyl fumarate, natalizumab, or sphingosine-1-phosphate receptor modulators fingolimod, ozanimod, and siponimod can be vaccinated at any time during their treatment, despite the likely vaccine response attenuation. However, in MS patients scheduled to start ocrelizumab therapy, the two-dose vaccine regimen should be administered at least 4–6 weeks before the initiation of their treatment course, or at least 4–6 months after the treatment course last ocrelizumab infusion. In patients treated with immune-reconstitution therapies, including alemtuzumab, and oral cladribine, it is better to delay vaccination until at least six months after the last course of treatment. In patients on high-dose or long-term corticosteroids, vaccination should be delayed until 4–6 weeks after treatment. Nonetheless, if these patients are not on DMTs, they should receive the SARS-CoV-2 vaccine as soon as possible.

There are theoretical concerns that mRNA-based Covid-19 vaccines may trigger the development of de novo neurodegenerative or neurologic disorders, such as demyelinating diseases or fever-induced seizures. In this case, the potential vaccine-induced adverse reaction could be even more debilitating than the viral infection. The adjuvants used in vaccines, including anti-SARS-CoV-2, might be responsible for potential neurologic adverse effects. Another potential neurological adverse event that may result from vaccination is the immunisation stress-related response (ISR), which manifests itself as psychogenic non-epileptic seizures (PNES).
myelitis, GBS, and Bell's palsy are other potential neurological consequences of the Covid-19 vaccination reported so far. Another potential adverse effect of these vaccines might be an exacerbation of MG and chronic inflammatory demyelinating polyneuropathy (CIDP). The demyelinating disease has most commonly been reported following viral-vector vaccines, which should be further investigated.

8 | PSYCHIATRIC DISORDERS

Patients with psychiatric disorders, especially those with severe mental disorders, such as bipolar, schizophrenia, and major depressive disorders, are at increased risk of being infected with Covid-19. Those with severe mental illnesses who were taking antipsychotics at increased risk of mortality from Covid-19 which may be associated with patients' different lifestyles, habits, cognitive impairment, difficulties in adhering to infection control measures, and these population's socioeconomic status. In addition, neuropsychiatric disorders and inflammation correlate, which could be a risk factor for more morbidity and mortality in these patients. Therefore, these patients should be prioritised for Covid-19 vaccination to minimise the risk of infection and transmission to other people. However, comorbid mental disorders have often been overlooked and underestimated in research evaluating the predictors of the severity and mortality from Covid-19. In many countries, institutionalised patients are listed high in the vaccination list, second only to healthcare personnel.

It must be noted that vaccinating patients with psychiatric disorders may also cause some concerns, as the efficacy, safety, and durability of the Covid-19 vaccine are not yet known in these patients. Moreover, vaccinating these patients may also give them the false belief that they are fully protected against the disease, and thus, they may be more likely to ignore hygiene protocols. Previous studies have shown a diminished antibody response to influenza and hepatitis vaccines in those with severe mental health issues. Nevertheless, there are currently no published studies about the efficacy of Covid-19 vaccines among patients with neuropsychiatric disorders. The relationship between vaccine response and psychotropic medications seems paradoxical. For example, antipsychotic agents (e.g., clozapine) might be associated with a syndrome resembling common variable immunodeficiency (CVID) in some patients that may lead to the suppression of vaccine-induced antibody formation. At the same time, antidepressant treatment might normalise the vaccine-induced immune response.

9 | DIABETES MELLITUS

Patients with diabetes mellitus, due to their comorbidities and acquired immunodeficiency, are at increased Covid-19-related morbidity and mortality. Diabetes is one of the comorbidities most associated with adverse outcomes in Covid-19 patients. However, there seems to be no difference in the severity or mortality of SARS-CoV-2 infection, based on whether they have diabetes type 2 (DMT2) or type 1 (DMT1). Nonetheless, the CDC prioritised vaccination among patients with DMT2 over those with DMT1. Therefore, vaccination is critical and necessary for this population, and endocrinologists should encourage their patients to be vaccinated as soon as possible. It appears that the immune response following Covid-19 vaccination is not affected by the serum glucose levels, as diabetic patients show an optimal antibody response. Furthermore, Covid-19 infected patients are at increased risk of developing new-onset diabetes. Therefore, vaccination can also help to prevent an increase in diabetes mellitus in the community.

10 | OBESITY

The association between obesity and viral infections was first demonstrated during the H1N1 epidemic in 2009, with the more body fat, the higher the risks of developing more severe illness and more extended hospitalisation in an intensive care unit (ICU). The reason behind this association was thought to be the impairment of humoral and cellular immunity, along with lower vaccine-induced immunity in these patients. Another reason could be the marked rise of angiotensin-converting enzyme 2 (ACE2) expression associated with high-fat diets. Another factor that plays a crucial role in making obese children more susceptible to infections, such as Covid-19, is hyperinsulinism, which is due to the compensatory mechanisms of their pancreatic β cells to overcome insulin resistance in their body. Thus, when higher amounts of insulin are required in intense metabolic activity, such as activating immune cells in response to the SARS-CoV-2 infection, their β cells cannot produce more insulin, as they are already working near their limit. Moreover, SARS-CoV-2 can enter the pancreatic β cells via ACE2 receptors, causing virus-triggered cell death or immune-mediated loss of infected pancreatic β cell mass. Insulin resistance in these patients can also impair the anti-inflammatory and vasoactive characteristics of nitric oxide (NO) by reducing phosphatidylinositol 3-kinases (PI3K).

Previous research has shown obesity as prevalent comorbidity among patients admitted into the ICU, especially among children and adolescents. This research shows that a higher BMI may increase the likelihood of getting a severe disease. Furthermore, a high BMI correlated with an increased need for mechanical ventilation in Covid-19 patients, with about 85% of patients with a BMI > 35 kg/m² requiring mechanical ventilation. It is noteworthy that this correlation was independent of age, gender, or the presence of any other comorbidities and has been confirmed elsewhere. Thus, it is recommended that obese individuals, especially those with higher BMIs, be prioritised for Covid-19 vaccination.
11 | CARDIOVASCULAR DISEASES

Cardiovascular disorders (CVD) and hypertension are among the comorbidities with the highest risks of adverse outcomes from SARS-CoV-2 since most of these patients are of advanced age and have metabolic or other underlying diseases. Therefore, this group should also be prioritised for Covid-19 vaccination. Patients who have had a recent hospitalisation, primarily in the previous six months, those with NYHA III-IV pulmonary hypertension, high grade peripheral arterial disease (PAD), morbid obesity, stage C heart failure, 1- or 2-vessel obstructive coronary artery disease (CAD) with angina, and poorly controlled diabetes, are among the most critical group of cardiovascular patients for vaccination. There have been no published studies on the type of Covid-19 vaccine most suitable for these patients.

12 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE

A 2020 study published in the European Respiratory Journal reported that the ACE2 receptor, a molecule found on the surface of lung cells, is the point of attachment for SARS-CoV-2. People with Chronic Obstructive Pulmonary Disease (COPD) and current smokers have increased airway expression of this enzyme. Although the up-regulation of this receptor is essential in protecting against acute lung injury, it predisposes individuals to increased risk of SARS-CoV-2 infection since this receptor is used as the gateway into the epithelial cells, explaining, at least in part, the increased risk of viral respiratory tract infection in active smokers and virus-related exacerbations in those with COPD. A 2021 systematic review of 59 studies found that having COPD significantly increased the odds of poor clinical outcomes, including the risk of hospitalisation, ICU admission, and mortality. Nevertheless, a review of vaccine-related deaths by the CDC, as of January 8, identified 55 deaths, with COPD being among the most commonly reported comorbidities, alongside hypertension, dementia, diabetes, and heart failure. Of these deaths, 37 were reported among residents of long-term care facilities. However, the report concluded that the benefits of the Covid-19 vaccination outweighed the potential risks in the older frail populations. Therefore, the recommendation is that individuals with COPD be prioritised for Covid-19 vaccination, regardless of age and frailty.

13 | HUMAN IMMUNODEFICIENCY VIRUS

Patients with human immunodeficiency virus (HIV), similar to other comorbidities and immunocompromising conditions, are prone to severe Covid-19. However, the risk is higher in patients with advanced immunosuppression, defined as a CD4+ T cell count of <200/µL. Moreover, if they become infected with SARS-CoV-2, negative impacts on their antiretroviral treatments would also be expected. Unfortunately, few studies have investigated the safety and efficacy of the Covid-19 vaccines in this population. However, one study has reported the mRNA Covid-19 vaccines, such as the BNT162b2 vaccine, to be both immunogenic and safe in patients with HIV. Nevertheless, there remains some level of mistrust in these patients about Covid-19 vaccines, and therefore, discussing this issue with these individuals to address their hesitancy is essential.

14 | CURRENT SMOKERS

It is well established that cigarette smoking causes structural changes in the respiratory tract and decreases immune responsiveness, both systemically and locally within the lungs. Therefore, smoking is a significant risk factor for the proliferation of bacterial and viral infections. Previous studies evaluating the Middle East Respiratory Syndrome—Coronavirus (MERS-Coronavirus) outbreak found higher mortality rates among current smokers than non-smokers and those who had never smoked. A 2020 systematic review of five studies from China during the first 2 months of the SARS-CoV-2 pandemic found a possible association between current smokers and Covid-19. This included negative disease progression and adverse outcomes, such as increased ICU admission, the need for mechanical ventilation, and increased mortality when compared to non-smokers. Another recent study confirms these findings, reporting that smokers are overrepresented in fatalities, especially in populations where current smoking is high. The authors suggest that higher rates of Covid-19 would be expected in countries with a higher prevalence of smoking. A more recent study reported that cumulative exposure to cigarette smoke is an independent risk factor for increased hospital admission and death from Covid-19. Given the increased likelihood of contracting SARS-CoV-2 and the propensity for greater disease severity, it concerns that a study from the United Kingdom (UK) found that current smokers were more likely to be undecided or unwilling to be vaccinated against Covid-19. Jackson et al. suggest that due to the disproportionately high number of current smokers among socioeconomically disadvantaged groups, lower vaccination uptake in these clusters could exacerbate the already extant health inequalities. As a result, targeted interventions may be necessary to prevent the compounding of health inequalities in these populations. The recommendation for Covid-19 vaccination among otherwise healthy smokers is that vaccination should occur, and in some cases vaccination is understandably prioritised in this group.

15 | PREGNANCY AND BREASTFEEDING

Covid-19 can manifest itself in its most severe form during pregnancy. Moreover, unfavourable pregnancy outcomes, such as premature labour, myocardial injuries, preeclampsia, perinatal death, and vertical transmission to the foetus, have been reported in pregnant women with Covid-19. Therefore, the need to be vaccinated in
this population is extremely important. Although little is known about the efficacy and safety profile of SARS-CoV-2 vaccines in pregnant or lactating mothers, due to their exclusion from vaccine trials, individuals intending to become pregnant and breastfeeding women are advised to receive a Covid-19 vaccine, mainly if they are a member of a high-risk group (e.g., healthcare personnel). However, only the mRNA vaccines are approved in this subsection of the population.

Different countries have different policies for vaccinating pregnant women against Covid-19. For example, the American College of Obstetricians and Gynecologists (ACOG) recommends vaccination in pregnant and lactating women. The United States Food and Drug Administration (FDA) and the Advisory Committee on Immunisation Practices (ACIP) have left the option to vaccinate pregnant and lactating women. The South African Society of Obstetricians and Gynecologists has recommended vaccination in those pregnant and breastfeeding women at higher risk of exposure. Canada, Ireland, Germany, and the United Kingdom have left the decision-making to their physician to consider the individualised risk-to-benefit ratio. Austria has announced the contraindication of SARS-CoV-2 vaccination for pregnant and nursing women, while the Netherlands and Japan have also recommended vaccination in pregnancy.

Conversely, Israel has prioritised pregnant and lactating women for vaccination, while the Society for Maternal-Foetal Medicine strongly recommends vaccination in pregnant and lactating mothers. The Italian scientific societies have announced that breastfeeding does not interfere with Covid-19 vaccination, and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has allowed SARS-CoV-2 vaccination during breastfeeding. However, the Academy of Breastfeeding Medicine states that breastfeeding is safe and effective in the geriatric population. The World Health Organisation (WHO) states that there is currently insufficient data on this issue, and further studies are needed to recommend vaccination in this population. In general, it seems that Covid-19 vaccines with Emergency Use Authorisation (EUA), including Pfizer/BioNTech, and Moderna vaccines, are prioritised in eligible pregnant mothers, such as women older than 35 years, healthcare personnel, those with multiple gestation, cancer, chronic hypertension, chronic kidney disease, chronic obstructive pulmonary disease, cardiac diseases, immunodeficiency, autoimmune diseases, obesity, sickle cell disease, smoking, and diabetes mellitus.

Vaccinated pregnant mothers can pass the IgG antibodies produced to their offspring, with one case study reporting vertical transmission. It was also shown that the transplacental transfer of vaccine-induced antibodies to the newborn is more likely if the mother is vaccinated in the third trimester. Similar passive transfer of IgA or IgG antibodies has not yet been observed in breastfed infants. The Academy of Breastfeeding Medicine has stated that breastfeeding should not be ceased for individuals vaccinated against Covid-19. If vaccinated, it seems that pregnant and lactating women achieve comparable antibody levels to other individuals of their age. Therefore, after delivery, it is essential to follow up with vaccinated mothers and their newborns to investigate possible maternal and foetal complications related to the vaccine. The Joint Committee on Vaccination and Immunisation (JCVI) stated that individuals trying to conceive could also be vaccinated if they meet the eligibility criteria. These women can get pregnant even before the second dose of the vaccine.

### 16 | ELDERLY

Since the beginning of the Covid-19 pandemic, the elderly have been the most affected by the social distancing measures applied to prevent virus transmission. Government measures have caused isolation and loneliness, which have led to physical inactivity and depression in these individuals. Nevertheless, older individuals (i.e., >65 years old) have a high risk of Covid-19-related hospitalisation, ICU admission, and mortality due to comorbidities, poor nutrition, depressed immunity, and lower organ function. Moreover, the elderly are at higher risk of getting severe Covid-19 and are less likely to have an excellent response to vaccines. Moreover, some people reside in nursing homes, which puts them at increased risk of acquiring communicable infections, such as Covid-19. Therefore, prevention of SARS-CoV-2 infection seems to be the most desirable approach in these patients. There is substantial concern that these people would not achieve favourable protective immunity post-vaccination, considering this population’s relatively weak antibody response. However, despite the lower efficacy of the Covid-19 vaccine in the elderly, the vaccines are still effective against preventing mortality. Therefore, vaccination is strongly recommended for this age group, and all currently approved Covid-19 vaccines are safe and effective in the geriatric population.

### 17 | CHILDREN

Until the evolution of the most recent SARS-CoV-2 variants, it was believed that children did not become afflicted with Covid-19, or at least not in its most severe forms. Thus, paediatric vaccination did not seem to be necessary. Nonetheless, reports of more severe forms of the disease and increases in the hospitalisation of children due to the alpha (B.1.1.7) and delta (B.1.617.2) variants prompt the discussion of including them in the Covid-19 vaccination program and developing a suitable vaccine for this subsection of the population. Moreover, vaccinating children can decrease infection transmission to others, meaning producing herd immunity in the community. They can also be a tool to prevent postinfectious conditions, such as Kawasaki-like and toxic shock syndrome-like diseases, commonly referred to as multisystem inflammatory syndrome in children (MIS-C), occurring 2–4 weeks after SARS-CoV-2...
infection. However, if proved to be safe and effective, there are still significant challenges to persuade hesitant parents to accept the vaccination of their children.

Preventive measures, such as face masks, hand hygiene, and social distancing, are less applicable in pediatrics than adults since adults adhere more strictly to the health protocols. Therefore, the need for a vaccine for children seems to be increasingly important. Several factors should be considered in considering vaccine responses in children, including congenital or developmental disorders, nutritional status, and maturational changes. However, immunocompromised children are also likely to show lower antibody response to Covid-19 vaccines. Presently, no children younger than 12 years old have been enrolled in Covid-19 vaccination trials since it was believed that only older children were at risk of developing severe SARS-CoV-2 infection, and therefore, the vaccine trials could be extended to younger children at a later date. The FDA has approved Covid-19 vaccines for those older than 12 years, but the age limit can perhaps be lowered again after further research.

18 | ALLERGIC DISEASES

In the period December 14–23, 2020, almost 1.9 million doses of Pfizer/BioNTech Covid-19 vaccine were administered in the US, among which 21 cases of anaphylaxis were reported to the CDC, corresponding to an estimated rate of 11.1 cases per million. Allergic reactions to vaccines and medications can be caused by two primary mechanisms: IgE-mediated and IgE-independent pathways. These reactions are mainly triggered by non-active vaccine ingredients, such as formaldehyde, thimerosal, egg protein, and gelatin, rather than the active vaccine ingredients. Other ingredients commonly used in vaccines to improve their solubility in water are polyethylene glycol (PEG) and polysorbate. PEG is used in the Pfizer/BioNTech and Moderna mRNA vaccines to enhance the stability of the mRNA-containing lipid nanoparticles, while polysorbate 80 is used in the Oxford/AstraZeneca and Johnson & Johnson adenoviral vector vaccines. These substances can trigger IgE formation in the body, causing mast cell degranulation. Thus, skin testing for PEG and polysorbate could be an option to prevent such catastrophic events following vaccination against Covid-19.

The IgE-independent pathway is another proposed mechanism behind vaccine-related allergic reactions. In these cases, activating complement elements, including C3a, C4a, and C5a, would trigger these inflammatory responses. Hence, measuring serum tryptase and complement system elements may help diagnose vaccine-induced reactions following Covid-19 vaccination. This vividly highlights the importance of taking a detailed history of previous severe allergic reactions to an injectable medication, vaccine, or other allergens, mainly PEG- and polysorbate-containing agents, to help prevent these types of adverse events. Nevertheless, CDC recommends vaccinating individuals with a prior history of allergic reactions unless a positive skin test is present. In such cases, vaccination is contraindicated under the EUA.

19 | CONCLUSION

This article has highlighted that several high-risk population groups should be at the top of the priority list for receiving a vaccination. It was also demonstrated that significant research gaps in this topic require many more studies to determine whether these populations should receive Covid-19 vaccines.

ACKNOWLEDGEMENT
The authors would like to thank the clinical research development center of Imam Reza Hospital, Kermanshah University of Medical Sciences, and Infectious Diseases and Tropical Medicine Research Center of Health Research Institute, Babol University of Medical Sciences, for their kind support.

CONFLICT OF INTEREST
Terence T. Sio reports that he provides strategic and scientific recommendations as a member of the Advisory Board and speaker for Novocure, Inc. and also as a member of the Advisory Board to Galera Therapeutics, which are not in any way associated with the content or disease site as presented in this manuscript. All other authors have no relevant financial interests to be declared.

AUTHOR CONTRIBUTIONS
- Zeinab Mohseni Afshar: Data collection and writing the manuscript. Arefeh Babazadeh: Data collection and writing the manuscript. Alireza Janbakhsh: Data collection and helped with manuscript writing. Feizollah Mansouri: Data collection and helped with manuscript writing. Terence T. Sio: Contributed substantial revisions to the manuscript’s content. Mark J. M. Sullman: Contributed substantial revisions to the manuscript’s content. Kristin Carson-Chahhoud: Helped with manuscript writing and contributed substantial revisions to the manuscript’s content. Rezvan Hosseinzadeh: Data collection and helped with manuscript writing. Mohammad Barary: Data collection, helped with manuscript writing, and contributed substantial revisions to the manuscript’s content. Soheil Ebrahimpour: Design of the research study and supervision.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES

1. Sadeghi-Haddad-Zavareh M, Bayani M, Shokri M, et al. C-reactive protein as a prognostic indicator in COVID-19 patients. Interdiscip Perspect Infect Dis. 2021;2021:5557582. doi:10.1155/2021/5557582

2. Eftekhari SP, Kazemi S, Barary M, et al. Effect of hydroxychloroquine and azithromycin on QT interval prolongation and other cardiac arrhythmias in COVID-19 confirmed patients. Cardiovasc Ther. 2021;2021:6683098. doi:10.1155/2021/6683098

3. Javanian M, Bayani M, Shokri M, et al. Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study. Bratisl Lek Listy. 2021;122(1):34-38. doi:10.4149/BLL_2021_003

4. Incatì RA, Trevisan C, Del Signore S, et al. Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine. 2021;39(17):2325-2327

5. Sonani B, Aslam F, Goyal A, Patel J, Bansal P. COVID-19 vaccina-tion in patients with rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol Int. 2021;41(3):509-518. doi:10.1002/arcm.21838

6. Park JK, Choi Y, Winthrop KL, Song YW, Lee EB. Optimal time after the last methotrexate administration and seasonal influenza vaccination in patients with rheumatoid arthritis: post hoc analysis of a randomised clinical trial. Ann Rheum Dis. 2019;78(9):1283-1284.

7. Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases—a longitudinal study. Arthritis Res Ther. 2015;17(1):151. doi:10.1186/s13075-015-0663-9

8. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis. 2006;65(2):191-194.

9. Park JK, Lee YJ, Bitoun S, et al. Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(2):282-284.

10. Park JK, Choi Y, Winthrop KL, Song YW, Lee EB. Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial. Ann Rheum Dis. 2019;78(9):1283-1284.

11. Hua C, Barnette T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-1026. doi:10.1002/acr.22246

12. MOC C. The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleve Clin J Med. 2020;87(11):695.

13. Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006-2010. doi:10.1136/annrheumdis-2012-201950

14. Soy M, Keser G, Atagunduz P, et al. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol. 2021;40(9):3533-3545. doi:10.1007/s10067-021-05700-z

15. Curtis JR, Johnson SR, Anthony DD, et al. American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1. Arthritis Rheumatol. 2021;73(7):1093-1107. doi:10.1002/art.41734

16. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tocaci- tinib on pneumococcal and influenza vaccine responses in rheu-matoid arthritis. Ann Rheum Dis. 2016;75(4):687-695. doi:10.1136/annrheumdis-2014-207191

17. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-1648.

18. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(3):476-480. doi:10.1002/acr.21838

19. Terracina KA, Tan FK. Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol. 2021;3(7):e469-e470. doi:10.1016/S2665-9913(21)00108-9

20. COVID A. Vaccine Clinical Guidance Task Force: COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases; 2021.

21. Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509-518. doi:10.1002/acr.21839

22. Ribas A, Sengupta R, Locke T, et al. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 2021;11(2):233-236.

23. Ting FL, Uy CD, Bebero KG, et al. COVID-19 vaccine and patients with cancer. The Philippine Society of Medical Oncology (PSMO) Position Statement. 2021. https://psmo.org.ph/wp-content/uploads/2021/04/PSMO-Position-Statement-on-COVID-19-vaccine-and-cancer-patients-4.pdf

24. Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for pa-tients with cancer: benefits likely outweigh risks. J Hematol Oncol. 2021;14(1):38. doi:10.1186/s13045-021-01046-w

25. Desai A, Gainer JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-319. doi:10.1038/s41571-021-00487-z

26. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901-1912. doi:10.1016/j.cell.2020.10.049

27. Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22(5):581-583. doi:10.1016/S1470-2045(21)00155-8

28. Keam B, Kang CK, Jun KL, et al. Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. Clin Infect Dis. 2020;71(2):422-425. doi:10.1093/cid/ciz1092

29. Mohindra P, Buckey CR, Chen S, Sio TT, Rong Y. Radiation therapy considerations during the COVID-19 Pandemic: literature review and expert opinions. J Appl Clin Med Phys. 2020;21(5):6-12. doi:10.1002/acm.21289

30. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944-951.

31. Benotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti-SARS- CoV-2 antibody response after the first injection of an mRNA
COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99(6):1487-1489. doi:10.1016/j.kint.2021.03.014

32. Aslam S, Goldstein DR, Vos R, et al. COVID-19 vaccination in our transplant recipients: the time is now. J Heart Lung Transplant. 2021;40(3):169-171.

33. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. J Am Med Assoc. 2021;325(17):1784-1786. doi:10.1001/jama.2021.4385

34. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. J Am Med Assoc. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489

35. Danziger-Isakov L, Kumar D, Practice AICo. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019;33(9):e13563. doi:10.1111/ctr.13563

36. Heldman MR, Limaye AP. SARS-CoV-2 vaccines in kidney transplant recipients: will they be safe and effective and how will we know? J Am Soc Nephrol. 2021;32(5):1024-1024.

37. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine in kidney transplant recipients: official publication of the European Dialysis and Transplant Association-European Renal Association; 2021.

41. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020;202(2):149-161. doi:10.1111/cei.13495

42. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine: considerations for COVID-19 immunization in ESKD. Kidney Int. 2021;100(2):464-465. doi:10.1016/j.kint.2021.05.001

43. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864-870. doi:10.1177/13524585211003476

44. Heldman MR, Limaye AP. SARS-CoV-2 vaccines in kidney transplant recipients: will they be safe and effective and how will we know? J Am Soc Nephrol. 2021;32(5):1021-1024.

45. Herrero-Ayuso B, Fernandez-Lopez L, et al. Recombinant expression of beta2-microglobulin associated with neurological adverse events: a case report and literature review. Curr Pharm Sci. 2013;8(1):1-4.

46. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine in patients undergoing maintenance hemodialysis: a case report and literature review. Curr Pharm Sci. 2013;8(1):1-4.

47. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine: considerations for COVID-19 immunization in ESKD. Kidney Int. 2021;100(2):464-465. doi:10.1016/j.kint.2021.05.001

48. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864-870. doi:10.1177/13524585211003476

49. Hsu CM, Weiner DE, Aweh G, et al. COVID-19 vaccine: considerations for COVID-19 immunization in ESKD. Kidney Int. 2021;100(2):464-465. doi:10.1016/j.kint.2021.05.001

50. Krueger KM, Ison MG, Ghosein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis. 2020;75(3):417-425.

51. Windpessl M, Bruchfeld A, Anders HJ, et al. COVID-19 vaccines and kidney disease. Nat Rev Nephrol. 2021;17(5):291-293. doi:10.1038/s41581-021-00406-6

52. Kronibichler A, Anders H-J, Fernandez-Juárez GM, et al. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. In Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association; 2021.

53. Bader D, Roberts C, Sage J, et al. COVID-19 vaccine: considerations for COVID-19 immunization in ESKD. Kidney Int. 2021;100(2):464-465. doi:10.1016/j.kint.2021.05.001

54. De Serres G, Billard M-N, Gariépy M-C, et al. Nephrotic syndrome following four-component meningococcal B vaccination: epidemiologic investigation of a surveillance signal. Vaccine. 2019;37(35):4996-5002. doi:10.1016/j.vaccine.2019.07.017

55. Aydin MF, Yıldız A, Oruc A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021;100(2):464-465. doi:10.1016/j.kint.2021.05.001

56. Hartung HP, Aktas O. COVID-19 and management of neuro-immunological disorders. Nat Rev Neurol. 2020;16(7):347-348. doi:10.1038/s41585-020-0368-9

57. Sellner J, Jenkins TM, von Oertzen T, et al. Primary prevention of COVID-19: advocacy for vaccination from a neurological perspective. Eur J Neurol. 2021;28(10):3226-3229. doi:10.1111/ene.14713

58. Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864-870. doi:10.1177/13524585211003476

59. Advisory Committee on Immunization Practices (ACIP). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the united states. COVID-19 Vaccine; Vaccines & Immunizations. Centers for Disease Control and Prevention; 2021.

60. Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439. doi:10.1016/j.msard.2020.102439

61. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.

62. Morales FS, Koralnik U, Gautam S, Samaan S, Sloane JA. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neuroimmunol. 2021;356:1056-1061.

63. Ahiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864-870. doi:10.1177/13524585211003476

64. Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864-870. doi:10.1177/13524585211003476

65. Advisory Committee on Immunization Practices (ACIP). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the united states. COVID-19 Vaccine; Vaccines & Immunizations. Centers for Disease Control and Prevention; 2021.

66. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.

67. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.

68. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.

69. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.

70. Mihai-Oradescu V, Praca E, Stahel RA, et al. CD20-depleting therapy in autoimmune diseases. CD20-depleting therapy in autoimmune diseases. J Neuroimmunol. 2021;356:1056-1061.
103. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868-873. doi:10.1001/jamapediatrics.2020.1948

104. Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr. 2020;174(10):e202430. doi:10.1001/jamapediatrics.2020.2430

105. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020;288(1):128-138. doi:10.1111/joim.13063

106. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-1199. doi:10.1002/oby.22831

107. Bhatraju PK, Ghassmehieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-2022. doi:10.1056/NEJMc2004500

108. Busetto L, Bettini S, Fabris R, et al. Obesity and COVID-19: an Italian snapshot. Obesity (Silver Spring). 2020;28(8):1600-1605. doi:10.1002/oby.22918

109. Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. Obesity (Silver Spring). 2020;28(8):1606-1612. doi:10.1002/oby.22923

110. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi:10.1111/obr.13128

111. Nogueira S, Del-Ciampo LA, Ferraz IS, et al. COVID-19 and smoking: a population survey of UK adults. Nicotine Tob Res. 2021;23:1623. doi:10.1093/ntr/ntab039

112. Xu PP, Tian RH, Luo S, et al. Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020;10(14):6372-6383. doi:10.7150/thno.64833

113. Driggin E, Maddox TM, Ferdinand KC, et al. ACC health policy statement on cardiovascular disease considerations for COVID-19 vaccine prioritization: a report of the American College of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(15):1938-1948. doi:10.1016/j.jacc.2021.02.017

114. Leung JM, Yang CX, Tam A, et al. ACE2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. doi:10.1183/13993003.00688-2020

115. Brake SJ, Barnsley K, Lu W, et al. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Cov-19). J Clin Med. 2020;9(3). doi:10.3390/jcm9030841

116. Gerayelli VF, Mline S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. doi:10.1016/j.eclinm.2021.100789

117. Lv G, Yuan J, Xiong X, Li M. Mortality rate and characteristics of deaths following COVID-19 vaccination. Front Med (Lausanne). 2021;8:670370. doi:10.3389/fmed.2021.670370

118. Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic. Lancet HIV. 2020;7(5):e308-e309. doi:10.1016/S2352-3018(20)30105-3

119. Hoffmann C, Casado JL, Härter G, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22(5):372-378.

120. Sutton MY, Jones RL, Wolitski RJ, Cleveland JC, Dean HD, Fenton KA. A review of the Centers for Disease Control and Prevention’s response to the HIV/AIDS crisis among Blacks in the United States, 1981–2009. Am J Public Health. 2009;99(5):S531-S539. doi:10.2105/ajph.2008.157958

121. Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;S1198-743X(21)00423-7. doi:10.1016/j.cmi.2021.07.031

122. Bogart LM, Ojikutu BO, Tyagi K, et al. COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among Black Americans living with HIV. J Acquir Immune Defic Syndr. (1999). 2021;86(2):200, 207.

123. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206-2216. doi:10.1001/archinte.164.20.2206

124. Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18(1):574. doi:10.1186/s12889-018-5484-8

125. Shen BN, Iskandrani A, Kharaba A, et al. Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: demographic, clinical and survival data. J Epidemiol Glob Health. 2017;7(1):29-36. doi:10.1016/j.jegh.2016.05.002

126. Nam HS, Park JW, Ki M, et al. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis. 2017;58:37-42. doi:10.1016/j.ijid.2017.02.008

127. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20. doi:10.18332/tid/119324

128. Lowe KE, Zein J, Hatipoglu U, Attaway A. Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the Cleveland clinic COVID-19 registry. JAMA Intern Med. 2021;181(5):709-711. doi:10.1001/jamainternalmed.2020.8360

129. Jackson SE, Paul E, Brown J, Stepoe A, Fangcourt D. Negative vaccine attitudes and intentions to vaccinate against Covid-19 in relation to smoking status: a population survey of UK adults. Nicotine Tob Res. 2021;23:1623-1628. doi:10.1093/nttobres/ntab039

130. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107. doi:10.1016/j.ajogmf.2020.100107

131. Kotlyar AM, Grechukhina O, Chen A, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021;224(1):35-53.e3. doi:10.1016/j.ajog.2020.100107

132. Maykin MM, Heuser C, Feltovich H. With the society for maternal-fetal medicine health policy Advocacy. C Pregnant people desire the protection offered by SARS-CoV-2 vaccines. Vaccine. 2021;39(2):171-172. doi:10.1016/j.vaccine.2020.12.007

133. Cherivenak FA, McCullough LB, Bornstein E, et al. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients. Am J Obstet Gynecol. 2021;224(5):470-478. doi:10.1016/j.ajog.2021.01.027

134. Hughes BL, Swamy G, Eckert LON, Gyaam-Bannerman C, Turrentine M. Vaccinating Pregnant and Lactating Patients against COVID-19. The American College of Obstetricians and Gynecologists; 2021.

135. Obstetricians ACo, Gynecologists. Vaccinating Pregnant and Lactating Patients against COVID-19. Acog.org Practice Advisory; 2020.

136. Adhikari EH, Spong CY. COVID-19 vaccination in pregnant and lactating women. JAMA. 2021;325(11):1039. doi:10.1001/jama.2021.1658
138. Moodley J, Ngene N, Khaliq Q, Hunter M. An imperative to offer pregnant and lactating women access to the COVID-19 vaccination roll-out programme. SAMJ S Afr Med J. 2021;111(4).

139. Elwood C, Boucoiran I, VanSchalkwyk J, Money D, Yudin M, Poliquin V. SOGC committee opinion—COVID-19 in pregnancy. J Obstet Gynaecol Can. 2020. doi:10.1016/j.jogcc.2020.03.012

140. Poon LC, Yang H, Dumont S, et al. ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and pu-erperium: information for healthcare professionals—an update. Ultrasound Obstet Gynecol. 2020;55(6):848-862.

141. Royal College of Obstetricians and Gynaecologists. Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding. Royal College of Obstetricians and Gynaecologists Press; 2020.

142. Board NV. COVID-19 Vaccinations: Recommendations for Use by the National Vaccination Board. Federal Ministry of Republic of Austria in Social Affairs, Health, Care and Consumer Protection; 2021. https://www.sozialministerium.at/dam/jcr:36d52a194e20439fd39fd36d52a194e20439fd.pdf

143. Machida M, Nakamura I, Kojima T, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines (Basel). 2021;9(3):210. doi:10.3390/vaccines9030210

144. Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet Gynecol. 2021;137(3):408-414.

145. Davanzo R, Agosti M, Cetin I, et al. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies. Ital J Pediatr. 2021;47(1):45. doi:10.1186/s13052-021-00998-6

146. Rimmer A. Covid-19: Breastfeeding Women Can Have Vaccine after Guidance Turnaround. British Medical Journal Publishing Group; 2021.

147. Blumberg D, Sridhar A, Lakshminrusimha S, Higgins RD, Saade G. COVID-19 vaccine considerations during pregnancy and lactation. Am J Perinatol. 2021;38(6):523-528. doi:10.1055/s-0041-1726390

148. Turcuy JM, Robles A, Herzc D, D’Alton M, Forman EJ, Williams Z. The emotional impact of the ASRM guidelines on fertility patients during the COVID-19 pandemic. Fertil Steril. 2020;114(3):e63. doi:10.1016/j.fertnstert.2020.08.194

149. Strategic Advisory Group of Experts (SAGE). The Moderna COVID-19 (mRNA-1273) Vaccine: What You Need to Know. World Health Organization; 2021. www.who.int/news-room/features-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know

150. Stafford IA, Parchem JG, Sibai BM. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. Am J Obstet Gynecol. 2021;224(5):484-495. doi:10.1016/j.ajog.2021.01.022

151. Paul G, Chad R. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination—a case report. BMC pediatrics. 2021;21(1). doi:10.1186/s12887-021-02618-y

152. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol. 2021;225:192-194. doi:10.1016/j.ajog.2021.03.035

153. Male V. Are COVID-19 vaccines safe in pregnancy? Nat Rev Immunol. 2021;21(4):200-201. doi:10.1038/s41577-021-00525-y

154. Golan Y, Prahl M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pediatr. 2021;175(10):1069. doi:10.1001/jamapediatrics.2021.1929

155. Zipursky JS, Greenberg RA, Maxwell C, Bogler T. Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making. CMAJ (Can Med Assoc J). 2021;193(9):E312-E314. doi:10.1503/cmaj.202833

156. Dashraath P, Nielsen-Saines K, Madhi SA, Baud D. COVID-19 vaccines and neglected pregnancy. Lancet. 2020;396(10252):e22. doi:10.1016/S0140-6736(20)31822-5

157. Girling J. COVID-19 vaccination in pregnancy. Drug Ther. Bull. 2021;59(6):82-82. doi:10.1136/dtb.2021.000002

158. Hawton A, Green C, Dickens AP, et al. The impact of social isolation on the health status and health-related quality of life of older people. Qual Life Res. 2021;20(1):57-67. doi:10.1007/s11136-010-9717-2

159. Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). In: Saxena SK, ed. Coronavirus Disease 2019 (COVID-19). Springer Nature; 2020. doi:10.1007/978-981-15-4814-7_3

160. Dhama K, Patel SK, Kumar R, et al. Geriatric population during COVID-19 pandemic: problems, considerations, exigencies and beyond. Front Public Health. 2020;8. doi:10.3389/fpubh.2020.574198

161. Rolland Y, Cesari M, Morley JE, Merchant R, Vellas B. COVID19 Vaccination in Frail People. Lots of Hope and Some Questions. Springer; 2021.

162. Dhakal S, Klein SL. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol. 2019;93(21):e00797-19. doi:10.1128/JVI.00797-19

163. Sadarangani M, Abu Raya B, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. 2021;39(15):2020-2022. doi:10.1016/j.vaccine.2021.03.020

164. Cooper DM, Afghani B, Byington CL, et al. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res. 2021. doi:10.1038/s41390-021-01402-z

165. Brookman S, Cook J, Zucherman M, et al. Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people. Lancet Child Adolesc. Health. 2021;5(4):e9-e10. doi:10.1016/S2352-4642(21)00030-4

166. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (delta) variant COVID-19 outbreak associated with a gymnastics facility—Ohio, April-May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(28):1004-1007. doi:10.15585/mmwr.mm7028e2

167. Klass P, Ratner AJ. Vaccinating children against covid-19—the lessons of measles. N. Engl J Med. 2021;384(7):589-591.

168. Wong BLH, Ramsay ME, Ladhan SI. Should children be vaccinated against COVID-19 now? Arch Dis Child. 2021.

169. Blaisdell LL, Cohn W, Pavell JR, Rubin DS, Vergales JE. Preventing and mitigating SARS-CoV-2 transmission—four overnight camps, Maine, June–August 2020. MMWR (Morb Mortal Wkly Rep). 2020;69(35):1216-1220.

170. Ladhan SI, Amin-Chowdhury Z, Davies HG, et al. COVID-19 in children: an analysis of the first pandemic peak in England. Arch Dis Child. 2020;105(12):1180-1185. doi:10.1136/archdischild-2020-320042

171. Food and Drug Administration (FDA). Emergency use authorization (eua) of the moderna covid-19 vaccine to prevent coronavirus disease 2019 (covid-19): fact sheet for healthcare providers administering vaccine (vaccination providers). Food and Drug Administration (FDA); 2021. https://www.modernatx.com/covid19vaccine-eua-eua-fact-sheet-providers.pdf

172. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. J Am Med Assoc. 2021;325(8):780-781. doi:10.1001/jama.2021.0600
173. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. *J Allergy Clin Immunol*. 2000;106(3):591-592. doi:10.1067/mai.2000.108433

174. Tannenbaum H, Ruddy S, Schur PH. Acute anaphylaxis associated with serum complement depletion. *J Allergy Clin Immunol*. 1975;56(3):226-234. doi:10.1016/0091-6749(75)90094-9

175. Stone CA, Jr., Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. *J Allergy Clin Immunol Pract*. 2019;7(5):1533-1540. doi:10.1016/j.jaip.2018.12.003

176. Krantz MS, Liu Y, Phillips EJ, Stone CA, Jr. Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. *J Allergy Clin Immunol Pract*. 2020;8(4):1416-1419. doi:10.1016/j.jaip.2019.12.041

177. Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. *J Allergy Clin Immunol Pract*. 2021;9(4):1423-1437. doi:10.1016/j.jaip.2020.12.047

178. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1

**How to cite this article**: Mohseni Afshar Z, Babazadeh A, Janbakhsh A, et al. Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. *Rev Med Virol*. 2022;32(3):e2309. https://doi.org/10.1002/rmv.2309